Post by account_disabled on Mar 15, 2024 23:14:27 GMT -6
SEPTEMBER , , : The suspension of trials on the Oxford vaccine after finding a possible serious adverse effect has once again brought to the fore the problems of obtaining a vaccine that has high efficacy and effectiveness, few adverse effects and a reasonable cost. Some time ago (June ) I already pointed out how complicated it is to find a good vaccine and how dangerous it was to make predictions about whether it would be achieved, and even more so about when it would be achieved (Treatments and vaccines against COVID-: controversies and counterinformation) and I believe that this stoppage, which the laboratory already indicates is temporary, because in days it plans to restart the process, has put us back in the reality of things. Vaccines are based on the fact that many diseases generate more or less permanent immunity (defenses) that protect against a new infection by preventing it and/or making it less serious.
The case of COVID-, there is evidence that at least part of the population does not generate antibodies and/or they disappear very quickly, which has been seen in the seroprevalence study carried out in Spain and in the fact that evidenced reinfections, that is, the first thing we do not know is if a vaccine is achieved, it will have lasting protection and if not, how long its protective effect will last. The AOL Email List vaccine will be administered to millions of healthy people and therefore adverse effects, even infrequent ones, have to be evaluated very carefully. The second issue that is no less important is that the vaccine was administered to millions of healthy people and therefore the adverse effects, even the infrequent ones, have to be assessed very carefully and the risk/benefit of the vaccine in terms of health must be evaluated.
Then the current search for the vaccine occurs in an environment of great competition between pharmaceutical companies and even between countries and will have an impact on global geopolitical relations. That makes things worse because it produces many incentives to magnify the positive results and minimize the risks, which has already produced more than one problem with other medications. Therefore we will have to be very cautious with the results published by the companies that are judge and party in this matter. On the other hand, there are countries, including Spain within the EU, that are making purchases from pharmaceutical companies of these vaccines, which do not yet exist, with the idea of ​​guaranteeing a supply of them when they are operational.
The case of COVID-, there is evidence that at least part of the population does not generate antibodies and/or they disappear very quickly, which has been seen in the seroprevalence study carried out in Spain and in the fact that evidenced reinfections, that is, the first thing we do not know is if a vaccine is achieved, it will have lasting protection and if not, how long its protective effect will last. The AOL Email List vaccine will be administered to millions of healthy people and therefore adverse effects, even infrequent ones, have to be evaluated very carefully. The second issue that is no less important is that the vaccine was administered to millions of healthy people and therefore the adverse effects, even the infrequent ones, have to be assessed very carefully and the risk/benefit of the vaccine in terms of health must be evaluated.
Then the current search for the vaccine occurs in an environment of great competition between pharmaceutical companies and even between countries and will have an impact on global geopolitical relations. That makes things worse because it produces many incentives to magnify the positive results and minimize the risks, which has already produced more than one problem with other medications. Therefore we will have to be very cautious with the results published by the companies that are judge and party in this matter. On the other hand, there are countries, including Spain within the EU, that are making purchases from pharmaceutical companies of these vaccines, which do not yet exist, with the idea of ​​guaranteeing a supply of them when they are operational.